解读2012年儿童哮喘国际共识

Interpreting international consensus on pediatric asthma in 2012

2012年6月，哮喘变态反应和免疫国际联合会（iCAALL）发布了“儿童哮喘国际共识（International Consensuson Pediatric Asthma）”，这是由欧洲变态反应和临床免疫学会（EAACI）、美国变态反应哮喘和免疫学会（AAAAI）、美国变态反应哮喘和免疫学院（ACAAI）以及世界变态反应组织（WAO）所组成的专家组，根据2006年以来修订或颁布的国际代表性或区域性儿童哮喘指南所提出的儿童哮喘诊断和治疗方面的报告。儿童哮喘国际共识更加强调了哮喘治疗目标是疾病控制，需要定期评估及监测以调整治疗方案。大多数儿童经合理的药物治疗能控制症状和减少未来患病风险。表型特异性哮喘治疗是未来发展趋势。

In Jun. 2012 ,the International Collaboration in Asthma Allergy and Immunology（iCAALL） committee published＂ International Consensus on Pediatric Asthma＂. This report is a conceptual framework for the diagnosis and management of asthma in children based on the pediatric asthma guidelines revised or promulgated internationally or regional representatively since 2006, which was written by professors from European Academy of Allergy and Clinical Immunology （ EAACI ）, American Academy of Allergy, Asthma ＆ Immunology （ AAAAI ） , American College of Allergy, Asthma ＆Immunology（ACAAI） ,World Allergy Organization（WAO） and International Consensus on Pediatric Asthma （ICON） has made emphasis on that the target of asthma treatment is to control disease. To achieve the goal of asthma control ,we need to evaluate and monitor regularly in order to adjust the treatment plan. Most children with rational drug therapy can control symptoms and reduce future risk. Phenotypic asthma therapy is the future development tendency.